Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Affiliations

T-Cell Therapy Company Gains $100M in Venture Funds

A 2 year-old company developing treatments for cancer and other diseases that activate or suppress the immune system with genetically engineered T-cells is raising $100 million in its first venture funding round. . . . → Read More: T-Cell Therapy Company Gains $100M in Venture Funds

Celgene Acquires Cancer Drug Start-Up in $7B Deal

The biopharmaceutical company Celgene Corp. is acquiring Impact Biomedicines Inc., a developer of drugs to treat a type of blood-related cancer, in a deal valued as much as $7 billion. . . . → Read More: Celgene Acquires Cancer Drug Start-Up in $7B Deal

FDA Clears Targeted Breast Cancer Radiation Treatment

The U.S. Food and Drug Administration approved a device that sends high doses of radiation to cancerous breast tissue while sparing healthy tissue nearby. . . . → Read More: FDA Clears Targeted Breast Cancer Radiation Treatment

Phone Sensors Shown to Monitor Chemotherapy Effects

Catheter for chemotherapy (Rhoda Baer, National Cancer Institute)

21 December 2017. A group of cancer patients was able to monitor the severity of effects of their chemotherapy with built-in sensors on smartphones and fitness trackers. Results of the clinical study, led by researchers at University of Pittsburgh, appear in the 19 December issue of . . . → Read More: Phone Sensors Shown to Monitor Chemotherapy Effects

Biotechs Partner on HPV Cancer Immunotherapies

Biotechnology companies in the U.S. and the Netherlands are collaborating on treatments for cancers caused by a type of human papillomavirus, or HPV. . . . → Read More: Biotechs Partner on HPV Cancer Immunotherapies

CAR T-Cells Shown Effective in Long-Term Studies

Results from two clinical studies of engineered immune system cells show patients continue to respond their treatments after 6 months or more. . . . → Read More: CAR T-Cells Shown Effective in Long-Term Studies

Cell Programming Company Raises $49.5M in Early Funds

A start-up enterprise creating add-on treatments that program the effects of cell and gene therapies is raising $49.5 million in its first venture funding round. . . . → Read More: Cell Programming Company Raises $49.5M in Early Funds

FDA Approves Precision Solid Tumor Cancer Diagnostics

The Food and Drug Administration approved genomic tests for solid tumor cancers that identify the most promising available therapies matched to the tumor’s genetic mutations. . . . → Read More: FDA Approves Precision Solid Tumor Cancer Diagnostics

Trial to Test Ultrasound/MRI for Brain Cancer

A developer of a technology that combines ultrasound and MRI scans plans to begin a clinical trial of its techniques to improve delivery of drugs to treat a form of brain cancer. . . . → Read More: Trial to Test Ultrasound/MRI for Brain Cancer

Genome Editing Enhances CAR T-Cells to Fight Cancer

A process using genome editing is shown to bolster cancer-fighting properties of T-cells from the immune system already modified to attack cancer cells. . . . → Read More: Genome Editing Enhances CAR T-Cells to Fight Cancer